



## RK SWAMY LIMITED

Regd Office: No. 19, Wheatcrofts Road, Nungambakkam, Chennai 600 034, Tamil Nadu, India  
CIN: L74300TN1973PLC006304, Email id: secretarial@rkswamy.com, Website: www.rkswamy.com

## STATEMENT OF AUDITED CONSOLIDATED &amp; STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015)

The Board of Directors at its meeting held on May 21, 2025 approved the audited financial results of the Company (Consolidated & Standalone) for the quarter and year ended March 31, 2025 ("Financial Results").

The Financial Results along with the Audit Report (Consolidated & Standalone), are available on the Company's website at [https://www.rkswamy.com/pdf/Financials\\_Results\\_FY\\_2024\\_25\\_Q4.pdf](https://www.rkswamy.com/pdf/Financials_Results_FY_2024_25_Q4.pdf) and on the websites of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com), respectively. The Financial Results can also be accessed by scanning QR code given below.

For and on behalf of the Board of Directors  
RK SWAMY LIMITED

sd/-

Place: Mumbai  
Narayanan Krishnaswamy  
Managing Director and Group CEO  
Date: May 21, 2025  
DIN: 00219883

## "IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

## NOTICE

## Fake Twitter (X) Profile impersonating Mr. Nilesh Shah, Managing Director, Kotak Mahindra Asset Management Company Ltd

It has come to the notice of Kotak Mahindra Asset Management Company Limited (KMAMC), the Investment Manager for the Schemes of Kotak Mahindra Mutual Fund (the fund), that there is a fake/ Deceptive/ fraudulent Profile created on social media platform i.e. Twitter (X) under the user name "Nilesh Shah (@mmary85074555580)", impersonating Mr. Nilesh Shah, Managing Director at Kotak Mahindra Asset Management Company Ltd and misusing name of Kotak.

The Profile has been formed along with likeness of the display picture of Mr. Nilesh Shah. Such profile is designed to defraud/Mislead Public.

This is to caution the public that KMAMC and Mr. Nilesh Shah has not authorized any person to undertake creation of the above-mentioned fake social media profile or undertake any activities related to the said profile. We would like to bring to the notice of public that KMAMC and Mr. Nilesh Shah are in no way associated with these fake Social Media profile created by these fraudsters and we condemn such acts as defrauding. We advise the general public to stay vigilant of such scams and exercise due caution. Kotak Mahindra Asset Management Company Limited shall not accept any responsibility or liability whatsoever for any loss that anyone may suffer or incur owing to any transactions made with such unknown individuals or agencies making false claims.

Please be advised that investments in Kotak Mahindra Mutual Fund can only be made through their official and registered addresses. For any inquiry you may visit our website at [www.kotakmf.com](http://www.kotakmf.com) or visit any of our branches.

For Kotak Mahindra Asset Management Company Limited  
Investment Manager – Kotak Mahindra Mutual Fund

Sd/-

Authorised Signatory

Mumbai  
May 21, 2025

Any queries / clarifications in this regard may be addressed to:

Kotak Mahindra Asset Management Company Limited  
CIN: U65991MH1994PLC080009 (Investment Manager for Kotak Mahindra Mutual Fund)  
6th Floor, Kotak Towers, Building No.21, Infinity Park, Off: Western Express Highway,  
Goregaon - Mulund Link Road, Malad (East), Mumbai - 400 097.

Phone Number: 18003091490 / 044-40229101 • Email: mutual@kotak.com • Website: [www.kotakmf.com](http://www.kotakmf.com)

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

## INTERGLOBE AVIATION LIMITED



CIN: L62100DL2004PLC129768

Registered Office: Upper Ground Floor, Thapar House, Gate No. 2,

Western Wing, 124 Janpath, New Delhi – 110001, India

Tel: +91 96500 98905; Fax: +91 11 4351 3200

E-mail: [investors@goidigo.in](mailto:investors@goidigo.in); Website: [www.goidigo.in](http://www.goidigo.in)

## AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2025

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of InterGlobe Aviation Limited ("Company") at its meeting held on Wednesday, May 21, 2025 approved the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2025 ("results").

The results, along with the Auditor's reports by M/s. S.R. Batliboi & Co. LLP, Statutory Auditors of the Company are available on the website of the Company at <https://www.goidigo.in/information/investor-relations.html>, and on websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively.

In compliance with Regulation 47 of the SEBI Listing Regulations, we hereby notify that the same can also be accessed by scanning the following Quick response (QR) code:



For InterGlobe Aviation Limited

Sd/-

Place : Gurugram

Date : 21 May, 2025

Company Secretary and Chief Compliance Officer



## MANKIND PHARMA LIMITED

Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4747 6600  
Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4684 6700  
Email: [investors@mankindpharma.com](mailto:investors@mankindpharma.com); Website: [www.mankindpharma.com](http://www.mankindpharma.com); CIN: L74899DL1991PLC044843

## EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

₹ in Crores except as stated otherwise

S. No.	Particulars	Consolidated				
		For the quarter ended		For the year ended		
		31.03.2025 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.03.2024 (Audited)
1	Revenue from operations	3,079.37	3,198.79	2,422.24	12,207.44	10,260.44
2	Profit for the period/year before tax	515.43	488.33	571.91	2,516.33	2,397.94
3	Profit for the period/year after tax	428.99	377.87	476.92	2,006.59	1940.79
4	Total comprehensive income for the period/year	410.73	395.45	468.23	2,002.83	1933.75
5	Paid up equity share capital	N.A.	N.A.	N.A.	41.26	40.06
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	14,291.13	9,323.03
	Earnings per equity share of face value of ₹ 1/- each					
7	- Basic EPS (in ₹)	10.20	9.45	11.76	49.28	47.75
	- Diluted EPS (in ₹)	10.18	9.44	11.74	49.20	47.68
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)		

The key standalone financial information is as under:

₹ in Crores except as stated otherwise

S. No.	Particulars	For the quarter ended		For the year ended	
		31.03.2025 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)	31.03.2025 (Audited)
1	Revenue from operations	2,126.59	2,414.41	2,007.47	9,497.80
2	Profit for the period/year before tax	428.75	525.09	519.83	2,305.99
3	Profit for the period/year after tax	382.46	412.02	444.44	1,884.25
4	Total comprehensive income for the period/year	379.19	421.43	460.52	1,950.46
5	Net worth (INR Crores)	14,640.27	14,253.85	9,702.77	14,640.27
6	Debt equity ratio (times)	0.50	0.71	0.00	0.00
7	Debt service coverage ratio (times)	0.12	289.52	208.49	0.55
8	Interest service coverage ratio (times)	2.29	3.27	102.37	5.88
					118.25

## Notes:

- The above is an extract of the detailed format of Audited Consolidated and Standalone Financial Results for the Quarter and Year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the Stock Exchanges website: [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and also on the Company's website: [www.mankindpharma.com](http://www.mankindpharma.com). Full Financial Results can also be accessed by scanning the QR Code given hereunder.
- The Audited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on May 21, 2025.
- The above Audited Consolidated and Standalone Financial Information is for continuing operations. Refer full format of the above Financial Results for discontinued operations.



For and on behalf of  
MANKIND PHARMA LIMITED  
Sd/-  
Ramesh Juneja  
Chairman and Whole Time Director  
DIN: 00283399

Place: New Delhi

Date: May 21, 2025



## ORIENT CEMENT LIMITED

Registered Office: Orient Cement Limited, Unit VIII, Plot No 7, Bhoi Nagar, Bhubaneswar, Odisha – 751012  
CIN: L26940OR2011PLC013933, Website: [www.orientcement.com](http://www.orientcement.com)  
Phone No.: +91 79 2656 5555, Email: [investors@orientcement.com](mailto:investors@orientcement.com)

Recommendations of the Committee of Independent Directors ("IDC") of Orient Cement Limited ("Target Company/TC") under Regulation 26(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("SEBI (SAST) Regulations") on the Open Offer (as defined below) made by Ambuja Cements Limited ("Acquirer") to the eligible public shareholders of the Target Company.

1 Date May 21, 2025  
2 Name of the TC Orient Cement Limited  
3 Details of the Offer pertaining to the TC Open offer for acquisition of up to 5,34,19,567 (Five Crore Thirty Four Lakh Nineteen Thousand Five Hundred and Sixty Seven) fully paid-up equity shares having a face value of INR 1 (Indian Rupee One) each ("Equity Shares") of Orient Cement Limited ("Target Company"), representing 26% (Twenty-six percent) of the Expanded Share Capital (as defined in the PA) from the Eligible Public Shareholders (as defined in the PA) of the Target Company by Ambuja Cements Limited ("Acquirer"), at a price of INR 395.40 (Indian Rupees Three Hundred and Ninety Five and Forty Paise) ("Offer Price") (the "Open Offer" or "Offer").

The public announcement dated October 22, 2024 ("PA"), the detailed public statement dated October 28, 2024 which was published on October 29, 2024 ("DPS"), the draft letter of offer dated November 6, 2024 ("DLOF"), and the letter of offer dated May 19, 2025 (issued on May 20, 2025) ("LOF") have been issued by SBI Capital Markets Limited on behalf of the Acquirer.

4 Name(s) of the Acquirer and PAC with the Acquirer Ambuja Cements Limited (Acquirer)  
There are no persons acting in concert (PACs) with the Acquirer for the purposes of the Open Offer.

5 Name of the Manager to the Open Offer SBI Capital Markets Limited  
Unit No. 1501, 15th Floor, A & B Wing, Parineet Crescendo Building, Plot C-38, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra, India  
Tel. No.: +91 22 4006 9807  
Website: [www.sbicaps.com](http://www.sbicaps.com)  
Email ID: [orient.openoffer@sicaps.com](mailto:orient.openoffer@sicaps.com)  
Contact Person: Raghavendra Bhat/ Aditya Deshpande  
SEBI Registration Number: INM00003531

6 Members of the Committee of Independent Directors "IDC" Mr. Ravi Kapoor, Chairperson  
Mr. Sudhir Navnati, Member  
Ms. Shruti Shah, Member  
All the members of the IDC are serving as Non-Executive Independent Directors on the board of the Target Company.

</







